ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs

被引:33
作者
Vautier, Sarah [1 ]
Fernandez, Christine [1 ]
机构
[1] Univ Paris 11, Fac Pharm, Dept Clin Pharm, EA2706, F-92296 Chatenay Malabry, France
关键词
ABCB1; antiparkinsonian drugs; BBB; genetic polymorphism; neurotoxicity; Parkinson's disease; pharmacokinetics; BLOOD-BRAIN-BARRIER; P-GLYCOPROTEIN EXPRESSION; MULTIDRUG-RESISTANCE GENE; MITOCHONDRIAL COMPLEX I; PREGNANE-X RECEPTOR; ANNONACEOUS ACETOGENIN; ATYPICAL PARKINSONISM; DOPAMINERGIC-NEURONS; ALZHEIMERS-DISEASE; ENDOTHELIAL-CELLS;
D O I
10.1517/17425250903193079
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
ABCB1/P-glycoprotein (P-gp) is an ATP-dependant transmembrane efflux protein widely expressed in human organs and plays a protective role against endogenous and exogenous substances. It is involved in drug pharmacokinetics affecting drug absorption, disposition and elimination. At the BBB level, due to its luminal localisation, ABCB1 limits drug transport and is important in central detoxification. Inter-individual variability has been described in ABCB1 expression and functionality. Recent work suggests that variability may play a role in the pathogenesis of neurological diseases. Furthermore, ABCB1 expression and/or functionality may modify drug efficacy or increase central adverse events. This paper reviews ABCB1 implication in the pathophysiology of Parkinson's disease and its role in the cerebral distribution of drugs.
引用
收藏
页码:1349 / 1358
页数:10
相关论文
共 88 条
[1]   Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA [J].
Bartels, A. L. ;
Willemsen, A. T. M. ;
Kortekaas, R. ;
de Jong, B. M. ;
de Vries, R. ;
de Klerk, O. ;
van Oostrom, J. C. H. ;
Portman, A. ;
Leenders, K. L. .
JOURNAL OF NEURAL TRANSMISSION, 2008, 115 (07) :1001-1009
[2]  
BARTELS AL, 2008, NEUROBIOL A IN PRESS
[3]  
Bauer B, 2004, MOL PHARMACOL, V66, P413
[4]   Chronic systemic pesticide exposure reproduces features of Parkinson's disease [J].
Betarbet, R ;
Sherer, TB ;
MacKenzie, G ;
Garcia-Osuna, M ;
Panov, AV ;
Greenamyre, JT .
NATURE NEUROSCIENCE, 2000, 3 (12) :1301-1306
[5]   Toxin-induced models of Parkinson's disease [J].
Bové J. ;
Prou D. ;
Perier C. ;
Przedborski S. .
NeuroRX, 2005, 2 (3) :484-494
[6]   Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans [J].
Brunner, M ;
Langer, O ;
Sunder-Plassmann, R ;
Dobrozemsky, G ;
Müller, U ;
Wadsak, W ;
Krcal, A ;
Karch, R ;
Mannhalter, C ;
Dudczak, R ;
Kletter, K ;
Steiner, I ;
Baumgartner, C ;
Müller, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (02) :182-190
[7]   Intestinal inflammation induces adaptation of P-glycoprotein expression and activity [J].
Buyse, M ;
Radeva, G ;
Bado, A ;
Farinotti, R .
BIOCHEMICAL PHARMACOLOGY, 2005, 69 (12) :1745-1754
[8]   Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy [J].
Caparros-Lefebvre, D ;
Sergeant, N ;
Lees, A ;
Camuzat, A ;
Daniel, S ;
Lannuzel, A ;
Brice, A ;
Tolosa, E ;
Delacourte, A ;
Duyckaerts, C .
BRAIN, 2002, 125 :801-811
[9]   Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats:: possible relevance for atypical parkinsonism in Guadeloupe [J].
Champy, P ;
Höglinger, GU ;
Féger, J ;
Gleye, C ;
Hocquemiller, R ;
Laurens, A ;
Guerineau, V ;
Laprévote, O ;
Medja, F ;
Lombès, A ;
Michel, PP ;
Lannuzel, A ;
Hirsch, EC ;
Ruberg, M .
JOURNAL OF NEUROCHEMISTRY, 2004, 88 (01) :63-69
[10]  
COMBATES NJ, 1994, J BIOL CHEM, V269, P29715